NCT03087942View on ClinicalTrials.gov

Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

August 7, 2018

Study Completion Date

August 7, 2018

Conditions
Renal Insufficiency
Interventions
DRUG

QAW039

450 mg

DRUG

QAW39A

450 mg

DRUG

QAW39A2107

450 mg

DRUG

QAW39A2107

450 mg

Trial Locations (2)

32809

Novartis Investigative Site, Orlando

67269

Novartis Investigative Site, Grünstadt

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY